Introduction The Texas Tech University Health Sciences Center (TTUHSC) is a public medical school headquartered in Lubbock, Texas, with additional campuses in Abilene, Amarillo, Dallas, El Paso, and the Permian Basin. It serves over 100 counties in the western region of Texas. Although TTUHSC is a separate entity from Texas Tech University, both universities are part of the Texas Tech University System, which includes four institutions. |
Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic vaccine | 1 |
Recombinant protein | 1 |
Vaccine | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
κ opioid receptor(Kappa opioid receptor) | 1 |
ISG15(ISG15 ubiquitin like modifier) | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism κ opioid receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ISG15 gene inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date30 May 2024 |
Sponsor / Collaborator |
Start Date15 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SchistoShield | Schistosomiasis More | Phase 2 |
Lm-LLO-ISG15 ( ISG15 ) | Renal Cell Carcinoma More | Preclinical |
AH-3193 ( κ opioid receptor ) | Neuralgia More | Preclinical |